Stem Cell Therapy Market to Reach $59.70 Billion by 2035

The global stem cell therapy market is expected to reach $59.70 billion by 2035, increasing from $18.13 billion in 2025, with a CAGR of 12.66% from 2026 to 2035. The growth is fueled by massive research investments, a surge in chronic disease incidence, and advancements in regenerative medicine, especially in oncology and neurology.

North America held the largest market share of 54% in 2025, while the Asia Pacific region is projected to grow at a CAGR of 10% from 2026 to 2035. The market is predicted to increase from $20.53 billion in 2026 to approximately $59.70 billion by 2035.

The adult stem cells (ASCs) segment accounted for 86.1% of the revenue share in 2025. ASCs are the market leader for their proven safety in treating cardiovascular diseases, neurological disorders, and orthopedic conditions, as well as for tissue repair and regeneration. The induced pluripotent stem cells (iPSCs) segment is expected to grow at a CAGR of 10% between 2026 and 2035. iPSCs are widely used for creating patient-specific treatments for regenerative medicine and overcoming immune rejection issues associated with other stem cell types.

The regenerative medicine application segment dominated with 93% market share in 2025. This segment growth is fueled by increasing adoption of cell and gene therapies to treat untreatable diseases. The drug discovery and development application segment is forecasted to grow at a CAGR of 10.2% from 2026 to 2035. This segment is primarily driven by the increasing incidence of chronic and rare diseases, forcing pharmaceutical companies to invest heavily in R&D.

The allogenic stem cell therapy segment held a market share of 59% in 2025. This therapy dominates the market, with rising cancer incidences and increasing clinical trials. This segment allows for mass production, reducing treatment time and expanding access for diseases like blood cancer.

CAR-T cell therapies are experiencing immense growth due to their superior potency in treating blood cancer and their ability to remain in the body to prevent recurrence. Recent innovations like stem cell-derived CAR-T cells are improving safety, persistence, and accessibility. These target specific antigens due to their enhanced precision, minimizing damage to healthy cells. This therapy is rapidly expanding into autoimmune disease, solid tumors, and infectious disease.

As of June 2025, more than 6,400 interventional cancer cell therapy trials were registered globally, with over 3,000 unique products under investigation. While CAR-T therapies continue to dominate the pipeline, the volume of their trials has started to fluctuate as developers prioritize optimization, manufacturing efficiency, and cost control over merely increasing trial numbers. Stem cell therapies rebounded to 29 trials in 2024, returning to previous peak levels. Regulatory milestones, such as the first approvals of TIL and TCR therapies in 2024, indicate that this phase of consolidation is leading to clinically validated and commercially viable treatment options.

The market is further expanded by various technological advancements like induced pluripotent stem cells (iPSCs) as an alternative to embryonic stem cells (ESCs). Remarkable investments from the private and government sectors in R&D alongside rapidly growing clinical trials are accelerating the innovation of new therapies.

The United States leads the North American region, witnessing a shift toward personalized medicine, with adult stem cells and induced pluripotent stem cells (iPSCs) driving innovation. Asia Pacific is the fastest region in demand for regenerative medicine, with supportive regulatory frameworks in countries like China and Japan, and advancements in personalized medicine. China is the leader in clinical applications, with the first mesenchymal stem cell therapy and the development of innovative diabetes treatments.

As cell and gene therapies move from clinical trials into routine care, health systems are discovering that scientific breakthroughs alone are not enough. A clinical pharmacy manager for hematologic malignancies and cellular therapeutics noted that one of the most common mistakes health systems make is focusing too heavily on the therapy itself. That imbalance can create serious gaps, including fragmented ownership across departments, immature referral and prior authorization workflows and underdeveloped financial models that fail to account for cash flow timing, denied claims or patient attrition.

Building a program is less about creating something entirely new and more about redesigning what already exists. A dedicated physical space can help, particularly for outpatient cell therapy, but it isn't always required at the start. What is essential is access to appropriate infusion areas, safe cold chain handling of products and clearly defined patient flow. Clarity of ownership, standardized workflows and leadership alignment are the real drivers of success.

On February 5, 2026, Keck Medicine of USC is investigating a unique stem cell therapy designed to repair damaged brain cells, specifically for Parkinson's disease. The treatment involves implanting lab-grown, dopamine-producing stem cells into the brain to restore motor function. The main goal is to reverse motor symptoms by restoring dopamine production, rather than just managing symptoms with medication.